The open-label, dose-escalation and expansion study, titled "A Phase 1/2 Study of ML-016 in Participants with Advanced Cancer ...
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) have ...
TORL BioTherapeutics LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, ...
US biotech TORL BioTherapeutics has raised $96 million in a series C round to push its lead antibody-drug conjugate, ...
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug ...
A biologics license application for pivekimab sunirine (PVEK) has been submitted to the U.S. Food and Drug Administration ...
RAJSHAHI, Oct 8, 2025 (BSS) - A total of 5,64,123 children aged between nine months and under 16 years are set to receive ...
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, ...
Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the ...
Researchers presented guidelines for vaccination against respiratory illness in individuals with cardiovascular disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback